Amerisource Bergen Corp.
ABC
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2026
May 6, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
6.8% upsideUndervalued by 6.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.15 Billion |
|---|---|
| Enterprise Value | $46.71 Billion |
| Dividend Yield | $1.94 (0.83%) |
| Earnings per Share | $8.02 |
| Beta | 0.56 |
| Outstanding Shares | 194,545,000 |
Return
| Return on Equity | 75.01% |
|---|---|
| Return on Assets | 3.12% |
| Return on Invested Capital | 9.43% |
Valuation & Multiples
| P/E Ratio | 21.5 |
|---|---|
| PEG | 16.71 |
| Price to Sales | 0.11 |
| Price to Book Ratio | 10.0 |
| Enterprise Value to Revenue | 0.14 |
| Enterprise Value to EBIT | 19.42 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 3.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5241▼ 38.87% |
|---|---|
| Total Calls | 2,499,247▼ 45.15% |
| Total Puts | 1,309,747▼ 68.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 91.57%▼ 3.60% |
|---|---|
| Total Invested | $33.23B▼ 3.78% |
| Investors Holding | 1,358▼ 40.00% |
ESG Score
No data
About Amerisource Bergen Corp.
22,000 employees
CEO: Steven Collis AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their part...
Relevant Senate Committees
This committee provides the crucial 'revenue estimates' and technical analysis for all tax legislation, directly influencing corporate tax structures, capital investment incentives, and the overall tax burden on large companies like AmerisourceBergen. Its work shapes the financial environment in which the company operates.
This committee holds immense power over corporate valuations through tax policy. More critically for AmerisourceBergen, it influences healthcare and retail sectors through Medicare pricing policies, which directly impacts the profitability and reimbursement structures for pharmaceutical products across the entire supply chain. Trade policy also impacts global operations.
This committee's subcommittees determine the precise allocation of discretionary federal spending. These decisions directly fund government agencies and programs (e.g., VA, DoD, NIH) that are significant customers or influence demand for AmerisourceBergen's pharmaceutical products and services, impacting its order books and revenue streams.
This committee's regulation of the FDA and oversight of drug approvals are absolutely critical to the pharmaceutical products that AmerisourceBergen distributes. Decisions regarding drug safety, efficacy, and market access directly impact the company's product portfolio. Labor laws also directly affect its large workforce.
As a large player in the pharmaceutical supply chain, AmerisourceBergen is subject to antitrust scrutiny. This committee's oversight of the DOJ, antitrust laws, and its influence on mergers and acquisitions (M&A) in the healthcare sector could directly impact the company's growth strategies and market position.
AmerisourceBergen is a core component of the pharmaceutical supply chain. This committee's investigations and hearings on drug pricing, healthcare costs for seniors, and long-term care quality directly create significant 'headline risk' and potential legislative pressure that could impact the company's revenue models and profitability.
As a major provider of pharmaceutical products and services, AmerisourceBergen could be a significant supplier to the Department of Veterans Affairs. This committee's funding decisions for the VA directly impact healthcare spending and procurement, creating substantial opportunities or risks for the company.